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This semester, the Law & Health Care Program (L&HCP) welcomed its newest faculty member, Natalie Ram. Professor Ram’s work is at the 
intersection of innovative biotechnology and the law. A Greenwall Faculty 
Scholar in Bioethics, Ram is a leading expert on genetic privacy and the 
law, publishing groundbreaking research in Harvard Law Review, Stanford 
Law Review, Columbia Law Review, Northwestern Law Review and Iowa 
Law Review, among others.
“We are very excited to have Natalie join our faculty,” said the program’s 
director Diane Hoffmann. “Her scholarship on the use of consumer genetic 
databases for law enforcement purposes raises profound privacy issues for 
individuals and families. Her work is at the cutting edge of health law and 
criminal law and has significant policy implications.” 
Most recently, she has gained national recognition for her work on issues 
related to law enforcement access to consumer genetic databases like 
23andMe, GEDmatch, and other DNA repositories. 
From the Director
The theme of our newsletter this fall is transitions. In this issue we highlight 
our new faculty hire, Professor Natalie Ram, and the new Law & Health 
Care Program Managing Director Rebecca Hall. As we welcome these new 
members to our health law community we also say goodbye to two long-
time faculty members who retired over the summer – Karen Rothenberg, 
founder and first director of the L&HCP, and Deb Weimer, director of the 
first law school AIDS clinic in the country. We also bid farewell to Lauren 
Levy, former managing director of the program who left to become the 
health officer for Cecil County, MD.  —Diane Hoffmann, Director
Continued on next page.
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“It’s really important to make clear 
the stakes that are involved when law 
enforcement can exploit genetic data 
in new ways,” says Ram. “We should 
carefully consider those stakes before 
we rubber stamp these new kinds of 
forensic methods and then find that 
we’ve sacrificed a whole lot of privacy 
that we did not intend to sacrifice.”
Professor Ram has written about 
recent site policy changes at the 
online genealogy website that law 
enforcement has recently begun to 
use to conduct a “forensic technique 
known as genetic genealogy: a 
method in which investigators 
try to link crime scene DNA to 
DNA from biological relatives in 
the hopes of generating leads for 
identifying suspects or remains.” 
Most famously, law enforcement 
pursued genetic genealogy to 
apprehend the man alleged to be the 
Golden State Killer, a moniker for 
a criminal supposedly responsible 
for more than 150 violent crimes in 
California between 1974 and 1986. 
Reflecting on this new means of 
solving crimes, Professor Ram raises 
important legal and ethical concerns 
about the constitutionality of such 
techniques and “the risks of putting 
so much decision-making power in 
the hands of a private entity.”
Since investigators cracked the 
decades-old Golden State Killer case 
in 2018 using familial identification 
DNA evidence obtained from 
GEDmatch, Ram has been consulted 
regularly by national media outlets. 
She has appeared on CNN, national 
radio broadcasts “Science Friday” and 
“Here & Now,” and been quoted in 
the Wall Street Journal, Washington 
Post, and BuzzFeed News. She 
also has written several op-eds for 
Slate and published articles in the 
scientific journals Science and Nature 
Biotechnology. In her most recent 
article for Slate, Professor Ram 
continues her important contributions 
to the evolving dialogue surrounding 
issues of innovative DNA technology 
and resulting privacy concerns.
 
Ram also is a leading voice in 
Maryland’s conversation around state 
regulations on law enforcement access 
to genetic databases. Last year, she 
published an article in the Maryland 
Bar Journal and was invited by a 
member of the Maryland House of 
Delegates to testify in Annapolis in 
support of a bill prohibiting familial 
searching in DNA databases.
As a former law clerk for Judge 
Guido Calabresi of the U.S. Court of 
Professor Natalie Ram Joins Law & 
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“I am excited about the possibilities that 
joining this program, 
the law school, and 
the University of 
Maryland—with its 
excellent medical 
school as well—will 
bring for my research 
and teaching.” 
Natalie Ram
Associate Professor of Law
Law & Health Care Program
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Appeals for the Second Circuit and 
then for Justice Stephen G. Breyer of 
the U.S. Supreme Court, Professor 
Ram also has a particularly well-
informed perspective on the criminal 
law implications of the use of such 
technology by law enforcement. 
In an interview with PBS, she 
discussed the 2018 Supreme Court 
decision in Carpenter v. United 
States, which held that warrantless 
searches of cellphone location data 
are unconstitutional invasions of 
reasonable expectations of privacy. 
She noted that “this ruling is likely 
to apply more broadly to deeply 
sensitive information shared with a 
third party, such as genetic data.” 
Ram has expanded upon this topic 
in numerous scholarly works and 
presentations, including her most 
recent article on the subject, “Genetic 
Privacy After Carpenter,” and her 
presentation on “(In)voluntariness in 
Forensic Genealogy” at the Harvard 
Law School’s Consuming Genetics 
conference in the spring of 2019.
In addition to her significant 
scholarly contributions to the field 
of bioethics and privacy, Professor 
Ram also brings her thorough 
and energetic teaching style to 
Maryland law students. Her teaching 
interests include bioethics, property, 
intellectual property, civil procedure, 
and criminal procedure. 
Professor Ram studied public and 
international affairs at the Woodrow 
Wilson School at Princeton 
University before receiving a JD from 
Yale Law School. After completing 
her clerkships on the U.S. Court of 
Appeals and the U.S. Supreme Court, 
Professor Ram practiced law at a firm 
in Washington, D.C. prior to her work 
as an assistant professor of law at the 
University of Baltimore School of Law.
 
Professor Ram is excited and delighted 
to join the University of Maryland 
Francis King Carey School of Law, 
and in particular about joining the 
excellent faculty in the Law & Health 
Care Program. “The Law & Health 
Care Program is well-established and 
widely-respected, and I am thrilled 
to count myself among its faculty. I 
am excited about the possibilities that 
joining this program, the law school, 
and the University of Maryland—
with its excellent medical school as 
well—will bring for my research and 
teaching.” ■
Professor Natalie Ram
Professor Natalie Ram Joins Law & Health Care 
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Professor Diane Hoffmann and Co-
Investigators Awarded $1.1M NIH Grant
In August, Professor Diane Hoffmann and an interdisciplinary 
team of co-investigators from the 
University of Maryland Baltimore 
(UMB) were awarded a $1.1 million 
grant from the National Institutes 
of Health’s (NIH) National Human 
Genome Research Institute for 
their project “Microbiome-Based 
Diagnostics: Stakeholder Perceptions 
and Implications for the Regulatory 
Framework.” The team will study 
the appropriateness and adequacy 
of current regulatory frameworks 
for microbiome-based diagnostic 
tests and develop comprehensive 
recommendations for improvement. 
This is the third NIH grant Professor 
Hoffmannn, who is the principal 
investigator (PI), and a number of her 
current coinvestigators, have received 
to address regulatory issues associated 
with new microbiome-based therapies 
and diagnostics. The first award was to 
explore regulatory issues for probiotics 
sold as food and dietary supplements, 
while their second grant focused 
on the regulation of microbiota 
transplants.
Microbiome research has led to 
promises of using the bacteria in 
an individual’s gut to diagnose 
or predict everything from that 
individual’s propensity for obesity 
to their mental health, sometimes 
through at-home testing kits. While 
much of the research in this area 
has focused on infectious disease 
diagnostics, more recent development 
has focused on tests to identify 
microbial characteristics or risk factors 
associated with non-communicable 
chronic diseases. There are now 
several commercially available 
microbiome-based personalized tests. 
Companies like Viome, DayTwo, 
uBiome, and Thryve have sold 
or are selling direct-to-consumer 
tests claiming to tell you what 
your microbiome looks like, how 
it compares to that of others, and 
what foods you should eat or dietary 
supplements you should take. These 
are not “diagnostic” tests, but more 
like informational or recreational tests, 
although some companies also try to 
sell you probiotics that “match up” 
with your microbiome profile. There 
are, however, numerous companies 
with diagnostics in various stages 
of development that will be able to 
identify biomarkers for cancer. Some 
of these tests must be ordered by a 
physician while others are direct-to-
consumer or are contained within 
“citizen science” projects that provide 
individuals with information on the 
composition of their microbiome 
if they consent to the use of their 
biological samples in research studies.
 
The new tests raise new ethical 
concerns that are similar to those 
raised in the early days of genetic 
testing – appropriate communication 
of test results, concerns about clinical 
validity and utility (particularly with 
regard to direct-to-consumer tests), 
informed consent, privacy and the 
potential for discrimination and 
stigma. The Genetic Information 
Nondiscrimination Act (GINA) of 
2008 was passed amid growing 
concern that information gleaned from 
genetic testing could result in the 
stigmatization or discrimination by 
employers and health insurers against 
individuals with particular health 
conditions. Could microbiome-based 
Law & Health Care Program
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diagnostics present a similar risk of 
stigma and discrimination? If so, will 
GINA apply to microbiome-based 
tests? 
Other concerns include the 
potential use of the tests to predict 
predisposition for disease based 
on microbial composition without 
offering any clinical utility. Or, the 
possibility that the test could uncover 
disease status or risk as an incidental 
or secondary finding. For direct-to-
consumer products, there is a risk 
that consumers will be misled by 
claims that are not supported by 
the research in addition to the risks 
associated with providing results to 
individuals who lack the expertise to 
understand them. Others have argued 
that providers ordering these tests 
may have insufficient expertise to 
interpret results and rely too heavily 
on the expertise of the commercial 
laboratories that sell the tests. In 
the context of “citizen science” 
initiatives, there are research ethics 
concerns particularly with regard to 
informed consent and the extent to 
which participants understand the 
downstream implications of providing 
biological samples particularly when 
many risks are as yet unknown.
The UMB team will utilize the 
expertise and resources of the Schools 
of Law, Nursing, Pharmacy, and 
Medicine and their proximity to the 
University of Maryland Medical 
Center to take a close look at the 
implications of this new field of 
diagnostics. The microbiome project 
will evaluate the existing legal and 
regulatory frameworks that apply 
to these new products and their 
use and assess patient and provider 
perspectives on their value, utility, and 
potential for misuse in order to inform 
future regulatory approaches for these 
tools and ensure their appropriate 
Professor Diane Hoffmann and Co-Investigators 
Awarded $1.1M NIH Grant, cont.
use in patients. The overall goal of 
the project is to inform and support 
policy and regulatory approaches 
that stimulate scientific discovery, 
identify and address problems or gaps 
in the current regulatory and legal 
framework, and encourage innovation 
while ensuring new microbiome-based 
products are safe and effective. ■ 
Professor Diane Hoffmann (PI)
Director, Law & Health Care Program
Jacob A. France Professor of Health Care Law
School of Law
Dr. Mary-Claire Roghmann
Professor, Department of Epidemiology and Public Health
Associate Dean, Transdisciplinary Research
School of Medicine
Dr. Erik von Rosenvinge
Assistant Professor, School of Medicine
Chief of Gastroenterology, VA Maryland Health Care System
 
Dr. Jacques Ravel
Professor and Associate Director for Genomics, Institute for 
Genome Sciences
School of Medicine
Dr. Ester Villalonga Olives
Assistant Professor, Pharmaceutical Health Services Research 
School of Pharmacy




Executive Director, Center on Drugs and Public Policy
School of Pharmacy
“Microbiome-Based Diagnostics: Stakeholder Perceptions and Implications for the Regulatory Framework.”
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Karen Rothenberg: A Legacy of Innovation 
and Passion
Professors Diane Hoffmann and Karen Rothenberg
This article is an excerpt from a 
larger piece by Diane Hoffmann 
written for the forthcoming issue 
of the Journal of Health Care Law 
and Policy devoted to the legacy of 
Professor Karen Rothenberg. 
Karen Rothenberg, the Marjorie Cook Professor Emeritus of Law, 
retired this summer after 36 years of 
teaching at the law school. Professor 
Rothenberg’s decades long career 
as a health law scholar, teacher, and 
mentor includes, among her many 
other impressive achievements, being 
the founding director of the Law & 
Health Care Program (L&HCP) and 
a former dean of the University of 
Maryland School of Law.
I write this article for the newsletter as 
someone who was mentored by Karen, 
who has benefited from her wisdom 
and advocacy, who has collaborated 
with her on policy initiatives, co-
authored articles with her, worked 
for her as associate dean, co-taught 
courses with her, and who has been her 
colleague and friend for over 30 years. 
A Career in Three Parts
Part 1
Karen started at the law school in 
1983, just a few years before me, and 
her plan was to develop and grow a 
law and health care program. She was 
prescient about the field of health law. 
After graduating from law school at 
the University of Virginia, she worked 
for the law firm of Covington & 
Burling, in Washington, D.C. where 
Charles Miller was her mentor. On 
reflecting on her time at the firm, 
Miller said: 
“I always knew that Karen was 
destined to be a leader in health law 
when she joined our firm in 1979 and 
told me she wanted to develop a health 
law practice before we knew there was 
such a field as health law. Karen had 
the vision to see that we were then on 
the brink of a great development in 
this field, and the energy to convert 
that vision into reality. Her decision 
to join the University of Maryland 
faculty and head up the Law & 
Health Care Program when no one 
could have told you what such a 
program really would or should 
entail further illustrates that she was 
a true pioneer and destined for great 
accomplishments.” 
In large part, I was hired to help 
Karen build the L&HCP. For the 
next dozen years, we worked closely 
together as colleagues developing the 
program, teaching and working on our 
scholarship. As an assistant professor, 
Law & Health Care Program
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Continued on next page.
“I always knew that Karen was destined to be a leader in health law when 
she joined our firm in 1979 
and told me she wanted 
to develop a health law 
practice before we knew 




Karen was incredibly prolific and, 
it seemed to me when I arrived, had 
already made a name for herself in the 
health law and policy academy. In the 
first four years of her professorship 
she had been a legal consultant for the 
American College of Nurse-Midwives, 
served on a National Institutes of 
Health (NIH) consensus panel on the 
use of diagnostic ultrasound imaging 
in pregnancy, and led a task force to 
plan a forum held by the NIH and the 
International Childbirth Education 
Association on Medical Malpractice 
Issues in Obstetrics.
During the next eight years she served 
on numerous boards, advisory and 
planning committees, and as an officer 
or leader in a number of health law 
organizations. These positions included 
the Board of Directors of the National 
Health Law Program, chair of the 
Association of American Law Schools’ 
section on Law, Medicine & Health 
Care, and member of the Institute of 
Medicine’s Committee on Legal and 
Ethical Issues Relating to the Inclusion 
of Women in Clinical Studies.
Early on in her career, Karen 
developed a relationship with a 
number of researchers and policy 
makers at the NIH and spent several 
sabbaticals and leaves (under the 
Intergovernmental Personnel Act) at 
different institutes there. The first was 
in the spring of 1991 when she worked 
at the National Institute for Child 
Health and Human Development. In 
the course of her work there, she met 
Elizabeth Thompson and became very 
interested in newly available prenatal 
genetic tests and the profound issues 
they raised for pregnant women. This 
experience was to be the foundation 
for much of her early and long-term 
scholarship. During this time, Karen 
was focused primarily on women’s 
health and reproductive issues and 
women in clinical trials. With the 
coming of the genetic revolution, 
Karen became embroiled in the world 
of prenatal genetic testing, co-editing 
her first book with Elizabeth Thomson 
on that topic. It was this work that led 
to what has become the scholarship for 
which she is most well-known: legal 
issues in research and clinical practice 
involving genetic testing and treatment. 
From September of 1995 until May 
of 1996 Karen spent the academic 
year at the NIH’s Office of Research 
on Women’s Heath as a special 
assistant to the director, Vivian Pinn. 
There she continued her work on the 
inclusion of women in clinical trials 
and expanded her scholarship on 
genetic issues. From 1995 to 1999, 
she published numerous articles on 
such topics as genetic discrimination 
and health insurance, the challenge of 
too much genetic information, genetic 
information and the workplace, cancer 
genetic susceptibility testing, privacy 
in genetics research, and cloning.
During this time, she also developed 
and honed certain positions on 
significant ethical issues created by 
genetic testing and genetic research. 
These included the idea that not all 
medical/genetic information is a 
good thing. This idea ran counter 
to the general medical view at the 
time that more information is better. 
However, Karen persuasively argued 
in a number of forums that sometimes 
people might not want to know that 
they are likely to develop a certain 
disease or disabling condition such 
as Huntington’s or Alzheimer’s, 
particularly when there is no cure for 
the disease. Karen also had strong 
concerns about discrimination based 
on the results of genetic testing and 
published several articles in the 
prestigious journal, Science, about the 
potential use of genetic test results 
by health insurers to deny individuals 
insurance and by employers who 
might choose not to hire someone 
with a predisposition to a serious 
genetic disease. 
Part 2
Karen’s concerns about the use of 
genetic test results to discriminate 
led her to help to lay the groundwork 
for legislation at the federal and 
state levels that would prohibit the 
use of such test results by insurers 
and employers. But her work on this 
important legislation was put on hold 
momentarily as she took over as 
interim dean (1999–2000) and then 
dean (2000–2009) of the law school. 
During this time Karen kept up her 
work on legal and policy issues arising 
out of the developments in genetics. 
In particular, she continued her 
advocacy for the Genetic Information 
Nondiscrimination Act (GINA), which 
was ultimately passed by Congress in 
Karen Rothenberg: A Legacy of Innovation and 
Passion, cont.
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2008, and worked with members of 
the Maryland General Assembly to 
pass similar legislation in Maryland.
While serving as dean, Karen 
somehow also managed not only to 
sit on the newly established Maryland 
Stem Cell Commission, but also 
to chair it – a time consuming and 
demanding job. It was a significant 
role which required establishing all the 
procedures, protocols, and policies by 
which the commission would allocate 
a several million-dollar budget to 
Maryland scientists performing stem 
cell research. Jack Schwartz, who 
sat on the Stem Cell Commission 
at the time Karen served as chair, 
wrote in a tribute to Karen about the 
controversy that enshrouded the effort 
to establish a stem cell commission 
in California but reported that “Karen 
had the discernment to know that the 
best path forward for the Maryland 
effort would be . . . quiet and steadfast 
professionalism – a scientifically sound 
grant review process, free of conflicts 
of interest and political agendas.”
Part 3
In the last phase of her career, after 
stepping down as dean, Karen married 
her love of theater with her passion 
for the ethical, legal, and social issues 
arising out of research and clinical 
practice related to genetics and 
devoted much of her scholarship to 
the use of plays to explore and mine 
those issues. She has written articles 
about plays that many of us have read 
or seen performed examining the 
scientific and ethical questions they 
raise, often foreshadowing some of 
the current dilemmas we face as a 
society in whether and how to regulate 
science. But she also sees plays as 
vehicles for examining relationships 
in ways that the study of science 
alone may not allow. Professor Frank 
Pasquale commented about how 
“Karen’s turn to literature recognizes 
that our plays and poems, stories and 
films, reveal patterns of power and 
meaning in the world by exploring the 
ramifications of critical relationships. 
They illuminate fundamental aspects 
of human experience.” While Karen 
explored the depths of existing 
literature to illustrate aspects of the 
human condition affected by science, 
she was not content to simply analyze 
the writings of others. In addition, 
she co-authored several original plays 
designed specifically to examine 
some of the intractable dilemmas 
that current genetics research and 
clinical practice raise. Often enlisting 
colleagues to play the actors in her 
theatrical productions, Karen used 
these plays as a way to generate 
conversations between scientists, 
bioethicists and health law academics 
and to help researchers understand the 
difficult decisions patients must make 
as a result of new genetic information 
and technologies. 
Also, in this phase of her career, Karen 
spent several years at the NIH as 
senior advisor to Eric Green, director 
of the National Human Genome 
Research Institute (NHGRI) and at 
the Clinical Center working with Ben 
Berkman and others. While there 
Karen developed “the idea for an 
intensive workshop where students 
would research and analyze a range 
of ethical, legal and policy questions 
raised by the increasing prevalence 
of human genome sequencing in 
research.” Karen called on several 
colleagues at the NIH to serve as 
supervisors for law students in a non-
traditional law school course that was 
part externship, part seminar and part 
clinic. In another tribute to Karen, 
Professor Michael Ulrich, a former 
student in this innovative class, says 
he felt empowered as a student to 
have the opportunity to work with 
these genetic experts on cutting edge 
genetic policy issues. He is just one of 
the many students Karen empowered 
and inspired in her years of teaching 
health law.
Conclusion
As Karen’s colleague for the last 32 
years I have truly been fortunate. I 
have been touched by her generosity, 
creativity, encouragement and 
friendship. The latter is something I 
treasure and hope will continue for 
many years to come. ■
Law & Health Care Program
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Professor Deborah Weimer, Founder of the First 
Legal Clinic for Persons with HIV/AIDS, Retires
Professor Deborah Weimer
Continued on next page.
Professor Deborah Weimer started teaching at the University of 
Maryland School of Law in 1988. 
She grew up on Long Island and 
put herself through college at State 
University of New York, as the first 
member of her immediate family to 
attend college, with a combination 
of jobs, scholarships, and loans. She 
attended law school at New York 
University during an exciting time. 
NYU law faculty and students were 
deeply involved in the civil rights 
movement, as well as the antiwar 
movement, and she worked with 
other students to create the New 
York University Public Interest Law 
Foundation, which funded public 
interest placements for lawyers, before 
graduating in 1978. 
Although Professor Weimer began 
her legal career with New York City’s 
largest municipal public employee 
union, she soon was awarded a grant 
by the NYU Foundation to provide 
legal assistance to disabled textile 
workers through the Brown Lung 
Legal Center in Columbia, South 
Carolina. There she trained lawyers 
handling workers’ compensation 
cases and worked hard to increase 
occupational safety protections and 
to make the workers’ compensation 
system more responsive.
 
In 1982, Professor Weimer joined the 
Palmetto Legal Services Program in 
Columbia, South Carolina, adding 
an employment law specialty to her 
practice. She litigated in federal 
and state courts, including wrongful 
discharge and Fair Labor Standard 
Act cases, and also handled a “general 
practice” legal services caseload, 
all while also chairing a statewide 
Employment Law Task Force. Early 
in her career, she was developing 
the multi-tasking skills 
that she has used all her 
professional life.
 
In 1985, Professor 
Weimer began a two-year 
Fellowship at Temple 
University School of Law, 
where she collaborated 
in teaching Civil Trial 
Advocacy, Bankruptcy, 
Property, and the 
Lawyering Process, which 
included brief writing and 
oral advocacy. There, she 
earned her LLM in Legal 
Education.
 
In 1987, she moved to 
Maryland and worked for 
seven months in a civil 
rights firm with LGBT 
clients before being 
hired at Maryland on a 
Department of Education 
grant to establish a medical-legal 
partnership at the Pediatrics clinic 
at what is now the University of 
Maryland Medical Center (UMMC). 
This was one of the earliest legal-
medical clinical partnerships in the 
country. Professor Weimer quickly 
expanded it to create one of the first, if 
not the first, law school clinics in the 
country serving patients with acquired 
immune deficiency syndrome (AIDS). 
When the three-year Department of 
Education grant ended, the Maryland 
Legal Services Corporation stepped 
in and has continued to fund it in 
significant part for almost 30 years.  
Because, especially in the 1980s 
and 1990s, AIDS was such a fatal 
disease, the focus of Professor 
Weimer’s clinics and Legal Theory 
& Practice courses included not only 
clients who had tested positive for 
human immunodeficiency virus (HIV), 
but also the children of those clients, 
including some children who were 
also HIV-positive, and grandparents 
of those children who had to assume 
parental responsibilities. These clinics 
have always had interdisciplinary 
components, and in one, a research 
component. One that focused on 
grandparent families included a formal 
study to test the effectiveness of the 
interdisciplinary approach, which 
Professor Weimer describes, because 
of this holistic approach, as one of her 
“most rewarding clinics.” This was a 
partnership with the Schools of Social 
Work and Nursing. 
Professor Weimer’s scholarship has 
grown out of her practice. She has 
been one of the leading scholarly 
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voices, in Maryland and nationally, on 
Standby Guardianship and Foster Care 
issues for HIV-infected children or the 
surviving children of parents who died 
of AIDS, among other topics.
She has received a number of 
awards for her extraordinary work, 
including the Maryland Legal Services 
Corporation’s Benjamin L. Cardin 
Distinguished Service Award, the 
University of Maryland Community 
Service Award, and the Maryland Bar 
Foundation’s Award for Professional 
Legal Excellence in the Advancement 
of Unpopular Causes. The National 
Jurist Magazine also recognized her 
AIDS Clinic in a national survey titled 
“Law Clinics that Make a Difference.” 
Her work also includes a voluminous 
amount of presentations, many on 
interdisciplinary panels, to a wide 
variety of audiences. 
It is daunting, if not impossible, to 
summarize her legacy, but several 
central themes emerge. 
1. Combining Legal Leadership 
in the Field and an Extraordinary 
Education for her Students 
Professor Weimer and her students 
became the legal leaders in Maryland, 
and early-on nationally, in the legal 
battle against AIDS and its tragic 
consequences. Today, our clinic retains 
that important role. With the advances 
of medicine, it is focusing on the legal 
obstacles people living with HIV 
face in getting life-saving medical 
care, like health insurance, stable and 
safe housing (i.e., no mold or lead 
paint), protection from employment 
discrimination, and SSDI benefits. 
Many of her former students, now 
lawyers practicing throughout 
Maryland and beyond, have said that 
Professor Deborah Weimer, Founder of the First Legal 
Clinic for Persons with HIV/AIDS, Retires, cont. 
their participation in her clinic was 
the critically important experience in 
persuading them to embark on legal 
services and public interest careers or 
to do substantial amounts of pro bono 
work in their private practices. 
2. Being a Reformer
From 1988 to 1995, Professor Weimer 
was a member of an interdisciplinary 
legislative advocacy committee that 
proposed and supported reforms in 
Annapolis. From 1993 to 1994 alone, 
she and her students played key roles 
in drafting and supporting Maryland’s 
Standby Guardianship Act, which 
allows a person facing death to provide 
for loved ones (for example, by 
avoiding the unnecessary placement of 
children in foster care), and Maryland’s 
Needle Exchange Pilot Program in 
Baltimore City, for which they drafted 
the legislation as a way to prevent 
the spread of HIV. They also won 
important court decisions, including 
those proscribing discrimination 
based on one’s medical condition and 
requiring informed consent for medical 
testing and treatment. 
3. Exemplifying Leadership and 
Partnership in the UMB Community
The list of Professor Weimer’s UMB 
partnerships is long. It includes not 
only the initial pediatrics project with 
UMMC, but also the Social Work and 
Nursing Schools’ grandparents’ project 
and the formation of many informal 
relationships among doctors and 
medical students, nurses and nursing 
students, social workers and social 
work students, and Professor Weimer 
and her law students. These have 
brought to life one of the purposes 
of a multi-graduate school campus 
to engage the disciplines in working 
with each other, which, in turn, helped 
make Maryland Carey Law’s Health 
Law and Clinical Law programs 
among the best in the country.
4. Introducing Students to the 
General Practice of Law 
Professor Weimer’s clinics have also 
introduced students to the types of 
general law practices that sustain 
solo and small firms, where many 
Maryland students may end up. 
This has been an important, often 
overlooked benefit, that AIDS clinic 
alumni have emphasized. There is 
no specialized body of “AIDS law.” 
Rather, the practice includes many 
subject matter practices: access to 
health care, housing, family law, 
benefits, guardianships, wills, anti-
discrimination laws, and more, all of 
which are integral parts of the AIDS 
clinic practice. 
 
5. Demonstrating Willingness to 
Take on New Challenges 
The willingness to take on new 
challenges has been a hallmark 
of Professor Weimer’s career, 
demonstrated most recently by her 
creation of a new Legal Theory 
& Practice course. Creatively, it 
combines property and health law 
issues, including the remediation 
of mold and lead paint, while also 
focusing on professional responsibility 
issues, specifically the misbehaviors 
of lawyers who oppose unrepresented 
parties. Students provide legal 
representation to tenants and 
write a semester paper about their 
experiences. She describes this course 
in a 2017 article in the Hastings and 
Poverty Law Journal, “Deepening 
Lawyer Role Education to Serve 
Students and Society.” 
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6. Modeling the Qualities of a Good 
Lawyer 
Above and beyond all of her 
other remarkable achievements, 
Professor Weimer remains a model 
of an extraordinary lawyer. She 
is committed to her clients, often 
working seven days a week, 52 weeks 
a year, and sometimes in 24-hour work 
days, to meet her commitments.
She always pays careful attention 
to ethical issues and demonstrates 
that ethical behavior is an essential 
part of law practice. She displays a 
Visiting Professor Matiangai Sirleaf Brings 
a Global Perspective to Maryland Carey Law
creativity and willingness to expand 
and diversify her practices and courses 
to meet unmet legal and educational 
needs. Through it all, she maintains 
an extremely high standard of 
professionalism while being a powerful 
advocate, and remains a superb 
example not only for her students, 
but also for her colleagues and every 
member of the legal profession.
 
Though she will be greatly missed by 
the law school community, Professor 
Weimer’s legacy will undoubtedly 
continue on through the Medical-
Professor Deborah Weimer, Founder of the First Legal 
Clinic for Persons with HIV/AIDS, Retires, cont. 
The Law & Health Care Program welcomes Professor Matiangai Sirleaf, who is a visiting associate professor of law 
for the 2019 fall semester. Professor Sirleaf brings her extensive 
scholarly expertise and practical experience in Global Public 
Health Law, International Human Rights and Criminal Law, 
and Post-Conflict and Transitional Justice, to the law school. 
She is currently an assistant professor of law at the University 
of Pittsburgh Law School, where she received the Chancellor’s 
Distinguished Research Award in 2019. Her work focuses 
on remedying the accountability and responsibility gaps that 
exist in international law. Her current research focuses on the 
disproportionate distribution of highly-infectious diseases and 
the role of law in facilitating this result. Professor Sirleaf was 
also recently awarded a Social Science Research Initiative grant 
for her proposal, “Understanding the Development and Impact 
of Neglected Tropical Diseases (NTDs) – 1950 to Present.” 
In addition, she was selected to present her paper “Disposable 
Bodies and Experimental Trials” at the 2019 Health Law Scholars 
Workshop jointly sponsored by St. Louis University School of 
Law and the American Society of Law, Medicine & Ethics. ■
Legal Partnership Clinic she created, 
as well as the impact she has had on 
so many former students, clients, and 
colleagues. Her impact on the Law & 
Health Care Program, law school, and 
state of Maryland will be felt for years 
to come. ■
Adapted from a tribute by Professor 
Michael Millemann.
Visiting Professor Matiangai Sirleaf
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Law & Health Care Program Welcomes New 
Managing Director Rebecca Hall 
The Law & Health Care 
Program is pleased 
to announce the 
appointment of Rebecca 
Hall as its new managing 
director. Hall is a 2013 
graduate of Maryland 
Carey Law and the health 
law certificate program, 
and has practiced health 
law in the Baltimore 
and DC area since graduation, first representing 
the University of Maryland Faculty Physicians in 
downtown Baltimore and, most recently, splitting 
her time between Rockville and Hunt Valley as senior 
associate counsel for the nation’s leading network 
of pain management practices. She also draws on 
her experience prior to and during law school, which 
includes work for UnitedHealth Group, the Medicaid 
Fraud Control Unit of the Maryland Office of the 
Attorney General, the Court of Special Appeals of 
Maryland, and the Maryland General Assembly.
During her time as a health law student, Hall 
participated in numerous health law competitions, 
including the inaugural Health Law Regulatory & 
Compliance Competition, and led the Journal of 
Health Care Law & Policy as its editor in chief. Since 
graduating, Hall has remained involved in the program 
as a repeat judge of the Regulatory & Compliance 
Competition, student mentor, competition team 
advisor, and internship supervisor. Hall is thrilled to 
return to the Health Law Program at this exciting 
time. On starting the job she remarked: “Having 
been involved in almost every aspect of the program 
as a student, alumnus, and mentor, I am extremely 
excited to return to the law school in this capacity 
to encourage the next generation of health lawyers 
while continuing to build on the program’s excellent 
reputation for producing outstanding scholarship 
and exemplary practitioners. I look forward to 
getting to know each and every health law student 
and to engaging with our extensive alumni network 
to continue the program’s leadership in health law 
education and scholarship in my hometown of 
Baltimore and nationwide.”  
Lauren Levy Leads Cecil 
County Health Office
In May, Lauren Levy, former managing 
director of the Law & Health Care Program, was 
appointed health officer for the Cecil County Health 
Department. Levy worked closely with Program 
Director Diane Hoffmann from July 2017 until May 
2019, overseeing the program’s externships and 
nurturing the Law & Health Care Program. The 
health officer position marks a return of sorts for 
Levy, who worked in public health research and 
program management for many years before 
returning to school to complete her law degree as 
an evening student. In her new role, Levy serves as 
the executive officer for the agency, which employs 
140 staff across six divisions. 
“It has been a steep learning curve,” Levy said. “The 
health department is involved in a diverse range 
of activities – from treatment for substance use 
disorder to STD testing to diabetes prevention and 
environmental health, among many others. I have 
learned a lot in just a few short months.”
Levy credits her training through the Law & Health 
Care Program with helping her to navigate the new 
role. “Having the grounding in health law and policy 
has been invaluable. I am relying on the research 
and analytical skills I developed as a student in the 
health law program on a daily basis.”
Levy is excited to stay involved with the health law 
program as a member of the policy committee of 
the Maryland Association of County Health Officers, 
a group that works closely with the Legal Resource 
Center for Public Health Policy, led by Professor 
Kathi Hoke. “It was a difficult decision to leave 
the Law & Health Care Program. I am so glad to 
have the opportunity to continue working with the 
program’s stellar 
faculty, staff 







Law & Health Care Program
Fall Newsletter 2019 Pg 13 
Pain & the Law: Professor Diane Hoffmann Shares 
Expertise with Audiences from Coast to Coast
Professor Diane Hoffmann, director of the Law & Health 
Care Program and Jacob A. France 
Professor of Health Care Law at the 
University of Maryland Francis King 
Carey School of Law, has written 
and spoken extensively about legal 
obstacles to, and gender disparity 
in, the treatment of pain. Over the 
summer, she shared her expertise on 
these topics in several fora.
 
On June 19, 2019, the University of 
Maryland, Baltimore (UMB) held 
a forum to share the work being 
conducted across disciplines on 
campus to better understand, treat, 
and modify the impact of chronic 
pain. Held in Baltimore, the event 
was moderated by Joel Greenberg, 
co-director of the University of 
Maryland Center to Advance Chronic 
Pain Research (CACPR). Professor 
Hoffmann was one of four expert 
panelists. Also presenting were Luana 
Colloca, associate professor at the 
University of Maryland School of 
Nursing and associate professor at 
the University of Maryland School 
of Medicine (UMSOM); Marcela 
Romero-Reyes, clinical associate 
professor at University of Maryland 
School of Dentistry (UMSOD) and 
clinical director of its Brotman Facial 
Pain Clinic; and Asaf Keller, professor 
at UMSOM. All are members of 
CACPR, and Hoffmann and Keller 
are on its executive committee. The 
multidisciplinary center is composed 
of nationally and internationally 
renowned clinical and preclinical 
translational scientists. The principal 
research focus of CACPR members 
is on the physiological, genetic, 
and psychosocial underpinnings of 
the development and persistence of 
debilitating chronic pain conditions.
Greenspan, professor and chair of the 
UMSOD Department of Neural and 
Pain Sciences, characterized chronic 
pain as a high-impact, complex 
problem affecting the quality of life of 
millions of U.S. residents who are kept 
from doing the things they need or 
want to do. “We’ve got a wide swath 
of talent,” he said, referring to UMB’s 
top-tier scientists and clinicians, 
adding that such breadth is needed to 
continue making progress.
Hoffmann spoke about the current 
state of chronic pain in the aftermath 
of the opioid epidemic and the 
crackdown by law enforcement 
on physicians prescribing large 
volumes of opioids. This in turn has 
frightened physicians, causing many 
to “stop seeing chronic pain patients 
or tapering them off of opioids 
involuntarily, literally abandoning 
them,” she said. “In some cases, such 
abrupt removal of opioid treatment 
has led to suicides,” she added. This 
kind of abandonment can be grounds 
for malpractice or action by state 
medical boards. Hoffmann attributed 
the situation in part to the actions 
of over half of state legislatures to 
codify specific dosage and duration 
limits for opioid prescribers based 
on a prescribing guideline issued 
in 2016 by the Centers for Disease 
Control and Prevention (CDC). The 
guideline, however, was intended as a 
discretionary suggestion for primary 
care providers not as a mandatory rule.
In response, last December, Hoffmann 
and colleagues published an article 
in STAT, “Overzealous use of the 
Professor Diane Hoffmann presenting at the CACPR’s June 19 Forum 
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CDC’s opioid prescribing guideline 
is harming pain patients,” about the 
situation and she and other pain-
treatment advocates urged adoption 
of more compassionate tapering, 
among other things. However, in 
April, she noted, authors of the CDC 
guideline, alarmed by reports of its 
misuse, published a commentary in a 
prominent medical journal advising 
against its misapplication, which, they 
acknowledged, can risk patient health 
and safety. “I’m hopeful this is a first 
step in efforts to rectify overzealous 
application of the CDC guideline,” she 
told the group.
Panelist Asaf Keller, from the School 
of Medicine, described an initiative of 
the University of Maryland Strategic 
Partnership: MPowering the State 
that supports both professionals in the 
field and university students across 
disciplines. “Clearly what is needed is 
a much more rational approach to pain 
management in general and to opioid 
prescription in particular. We are 
addressing this issue at all the schools 
on campus,” he said, describing ways 
of imparting knowledge necessary to 
apply this rational approach. Keller 
also outlined other efforts such as a 
“cuddling” initiative to help babies 
who are in misery after being born 
with neonatal opioid abstinence 
syndrome. These infants, born to 
mothers who used opioids during 
pregnancy, fare better if provided skin-
to-skin contact. “It’s very low cost, 
very low-tech,” he said.
Romero-Reyes, a researcher and 
clinician at the Dental School, said 
her focus is to provide evidence-based 
pain management for facial pain. Such 
pain can have multiple causes. “As 
a clinician, I have the opportunity to 
Pain & the Law: Professor Diane Hoffmann Shares 
Expertise with Audiences from Coast to Coast, cont.
see firsthand the needs of this patient 
population,” she said. “As a scientist, 
I’m able to translate those needs to 
research questions,” such as current 
studies on overcoming neuropathic 
pain.
Colloca, a faculty member at the 
School of Nursing, asked the group, 
“How can we better manage pain?” 
Demand is great for solutions beyond 
opioids, and a patient’s own mindset 
could be part of the solution. Colloca 
suggested that patients be asked 
to describe their pain levels not as 
a number, ascending from mild to 
severe, but rather as a ranking of 
everyday activities they can do. 
She also proposed thinking about 
approaches to help people increase 
their tolerance of pain, perhaps by 
stimulating the brain to produce 
natural substances that combat pain 
messages or by distractions such as a 
virtual reality.
At the outset of the forum, guests at 
the event had a chance to try a virtual 
reality simulation used by Colloca in 
her research, as a potential distraction 
to pain. Several took part in a 
demonstration in which a headset took 
each individual to an undersea setting 
where a whale loomed overhead. 
Members of Colloca’s lab were eager 
to show off its research, which is also 
supported by MPowering the State.
During a question-and-answer session 
to conclude the event, guests shared 
observations and problems of their 
own or of family members who 
struggle with chronic pain. Patient 
Dante Wheatley was accompanied 
by his mother, dental assistant Kim 
Jones, and by her employer, Willie 
Richardson, DDS, who all spoke of 
how chronic, high-impact pain has 
affected Wheatley’s daily life.
Hoffmann also spoke at several other 
events related to chronic pain over 
the summer. In July, she spoke at the 
Healthy Women Science, Innovation & 
Technology Summit on Chronic Pain 
in Women, focusing her remarks on 
disparities in the treatment of women 
for chronic pain. On August 14th, 
Hoffmann traveled to Sacramento, 
California where she participated in 
a legislative briefing on chronic pain. 
Hoffmann, along with other pain 
experts including Sean Mackey, chief 
of the Division of Pain Management 
at Stanford University, Christin 
Veasley, director of the Chronic 
Pain Research Alliance, and Steven 
Richeimer, chief of Pain Medicine, 
University of Southern California, 
urged the California legislature to 
adopt several recommendations to 
improve chronic pain treatment. 
Hoffmann and these experts developed 
the recommendations as part of a 
California Pain Summit, held last 
November in Los Angeles by For 
Grace, a non-profit organization 
that advocates for better care and 
treatment of women with chronic pain. 
Hoffmann is on the Board of 
For Grace. ■
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The Public Health Law Clinic and Network for 
Public Health Law Continue to Influence State 
Policy on Cannabis Regulation
Professors Mathew Swinburne and Kathleen Hoke
In 2014, the Maryland General Assembly passed legislation 
permitting the use of cannabis for 
certain medical conditions and 
the creation of a medical cannabis 
industry, from growers to distributors. 
The state’s medical cannabis system, 
which allows patients with qualifying 
conditions certified by an authorized 
health care provider to 
acquire cannabis from 
licensed dispensaries, 
opened for business in 
December 2017. Medical 
cannabis in Maryland has 
generated a whirlwind of 
legal, public health, and 
social justice issues, not the 
least of which is the fact 
that cannabis (marijuana) is 
still defined by the federal 
government as a “Schedule 
I drug,” “with no currently 
accepted medical use and 
a high potential for abuse” 
under the Controlled 
Substances Act, making it 
illegal under federal law 
to use, even for medicinal 
purposes. The University 
of Maryland Francis King 
Carey School of Law and the 
Network for Public Health 
Law have been at the forefront 
of addressing these complicated 
challenges to ensure a safe, efficient, 
and equitable medical cannabis system.
The Public Health Law Clinic, 
directed by Professor Kathleen Hoke, 
has been involved in Maryland’s 
medical cannabis program since its 
inception. The clinic has played a key 
role in educating Maryland’s public 
health community by tracking and 
reporting on cannabis legislation every 
session. In addition, under Professor 
Hoke’s guidance, clinic students 
have advocated for key cannabis 
legislation in Annapolis. This past 
session, clinic student John Travers 
’19 testified in support of legislation 
that would have authorized institutions 
of higher education and related 
medical facilities, like the University 
of Maryland, Baltimore (UMB), to 
conduct research related to medical 
cannabis. Clinic student Kevin Redden 
’20 testified in support of a Senate 
bill that would have prohibited the 
revocation of parole based on use or 
possession of cannabis for qualified 
patients and licensed individuals 
in the cannabis industry. Redden 
testified that punishing parolees who 
are certified patients or licensees 
within the state-created medical 
cannabis industry subverts the goals 
of the medical cannabis program and 
is detrimental to public health. The 
provisions in these bills were absorbed 
into a larger medical cannabis bill, 
Maryland House Bill 17/Senate Bill 
857, which passed in the State Senate 
and the House of Representatives. 
Governor Larry Hogan signed the 
legislation in April and it went into 
effect on July 1.  
In addition to her work 
with the Public Health Law 
Clinic, Professor Hoke is 
the executive director of the 
Network for Public Health 
Law’s Eastern Region. 
The Network for Public 
Health Law is a national 
organization funded by 
the Robert Wood Johnson 
Foundation. The network’s 
Eastern Region is housed in 
the law school. The network 
provides legal assistance on 
a broad spectrum of public 
health issues, including 
the regulation of cannabis. 
Eastern Region Associate 
Director Mathew Swinburne 
’08 is the network’s expert 
on the legal and public 
health issues associated with 
cannabis. He regularly meets 
with health departments, health 
care providers, hospitals, business 
and professional associations, law 
enforcement, and government officials 
to provide guidance on a myriad of 
legal challenges. The broad spectrum 
of concerns he hears about include 
illegal youth access, employment drug 
testing, medical cannabis use in public 
housing, product safety, and over-the-
counter sales of CBD products.
Given the outpouring of interest 
in legal issues raised by the state’s 
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medical cannabis program, the 
law school, the Network, and the 
Maryland Commission on Civil 
Rights co-sponsored a conference 
at Maryland Carey Law this past 
May. The conference focused on the 
evolving legal landscape for medical 
cannabis at the federal and state level, 
the science of medical cannabis, and 
issues of employment and housing 
law that impact employees and 
tenants who use medical marijuana. 
As a result of this conference and 
the network’s recognized expertise, 
Hoke and Swinburne were invited 
to be part of the Maryland Medical 
Cannabis Commission’s workgroup 
that is developing regulations for 
Maryland’s newly legalized edible 
cannabis products (e.g. cannabis 
infused cookies and candies). Edible 
cannabis products create unique 
public health challenges including 
their attractiveness to children, food 
safety concerns, and potential dosing 
problems. The Maryland Medical 
Cannabis Commission also posted 
draft regulations on edibles, which are 
available at http://bit.ly/2kp05Se.
Regulation of cannabis continues to 
advance in Maryland at a blistering 
pace. Several bills were introduced 
this past session to legalize 
recreational cannabis in Maryland, all 
of which died in committee. However, 
the General Assembly created a 
bipartisan workgroup of senators and 
delegates to study the implications 
of a recreational cannabis system 
The Public Health Law Clinic and Network for Public 
Health Law Continue to Influence State Policy on 
Cannabis Regulation, cont. 
School of Pharmacy Offers MS 
in Medical Cannabis
The University of Maryland, Baltimore (UMB) 
continues to lead the field of medical marijuana 
through initiatives in its other professional schools. 
The School of Pharmacy recently launched a new 
and unique Master of Science (MS) in Medical 
Cannabis Science and Therapeutics to provide 
students with the knowledge and skills needed 
to support patients and the medical cannabis 
industry, add to existing research in the field, and 
develop well-informed medical cannabis policy. The 
MS in Medical Cannabis Science and Therapeutics 
is the first graduate program in the country 
dedicated to the study of medical cannabis. It 
aims to meet the needs of all individuals interested 
in advancing their knowledge about medical 
cannabis, including health care professionals such 
as physicians, nurses, and pharmacists; scientists 
and regulators; growers and dispensary owners; 
and policy and industry professionals.
“Medical cannabis has been legalized in 33 states, 
including Maryland, as well as in Washington, 
D.C., Guam, and Puerto Rico,” says Natalie D. 
Eddington, dean and professor of the School 
of Pharmacy. “This number is only expected to 
increase in the future, fueling a demand for an 
educated workforce that is well-trained in both the 
science and therapeutic effects associated with this 
medicinal plant.
Graduates of the program will be able to help 
identify patients appropriate for medical cannabis 
therapy and determine appropriate dosing and 
administration for those patients; ensure the 
safe and effective design, development, and 
manufacture of medical cannabis products; identify 
potential research opportunities related to the 
science and health effects of the cannabinoids 
found in medical cannabis; and participate in 
health policy decision-making processes related to 
medical cannabis. Coursework will include a class 
on federal and state cannabis laws and policies. ■
and to make recommendations for 
potential legislation in 2020. Again, 
the legislature reached out for the 
network’s expertise. Swinburne 
conducted multiple presentations for 
the work group on federal regulation 
of cannabis and the variety of state 
approaches to regulating recreational 
cannabis use.
As the cannabis industry continues to 
grow and the laws regulating it evolve, 
the University of Maryland Francis 
King Carey School of Law and the 
Network for Public Health Law will 
continue to be a critical resource at the 
vanguard of this field. ■
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Kathleen Hoke
was quoted in Mother Jones’ “Juuls Campaign to Raise the Tobacco Age is More 
Complicated than it Seems” on August 22.
“Though legislation to raise the legal age for tobacco consumption to 21 may sound like a 
move to protect youth from harmful health effects, experts say it’s more complicated than that. 
‘We see that they want to put this out there to make it look like they’re the good guy,’ Hoke says. 
‘But they’re not really trying. They don’t expect it to really hurt their business.’ The legislation 
would have a ‘negligible’ impact on smoking, she says. Without dedicated enforcement—which 
fluctuates with state budgets and is complicated by the internet marketplace—raising the age 
limit may not do much. Raising the age to 21… could prohibit local governments from passing 
measures that could also alter teen use, like banning flavored tobacco.” 
Natalie Ram
was quoted in “Customers Handed 
Over Their DNA. The Company Let the 
FBI Take a Look” in The Wall Street 
Journal on August 22. 
“Taking a DNA test does not just tell a 
story about me. DNA tests inevitably reveal 
information about many other people 
too, without their consent,” says Natalie 
Ram, an associate professor of law at 
the University of Maryland Francis King 
Carey School of Law, who studies genetic 
privacy. “Should genetic databases be 
allowed to make up the rules as they go 
along?” … Ms. Ram, of the University of 
Maryland, thinks consumers should be 
required to take affirmative steps to opt in 
to law-enforcement matching, rather than 
having to decide to take steps to opt out.”
Frank Pasquale
was quoted in “Health Data Outside 
HIPAA: The Wild West of Unprotected 
Personal Data” in The Health Care Blog 
on August 12. 
“Quoted in the NCVHS report, Law 
Professor Frank Pasquale concluded 
that for health data outside the 
healthcare sector, ‘in many respects, it is 
anything goes.’”
Rena Steinzor
was quoted in Propublica’s “The Car Seat 
Industry Helped Delay a Child Safety 
Regulation — Again” on August 20.
“Consumer advocates have raised concerns 
about the delays. ‘I don’t understand why 
anyone hasn’t sued,’ said Rena Steinzor, 
a professor of administrative law at the 
University of Maryland School of Law. 
An agency can be sued for unreasonable 
delays in implementing regulations or 
for failing to meet a deadline specified by 
Congress. ‘Unless they are worried that the 
Trump [National Highway Traffic Safety 
Administration] would come up with a very 
weak rule,’ she added.” 
Health Law Faculty in the News
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At the 2019 Reception for Health Law Certificate Graduates, held 
at Westminster Hall on May 17, the 
Law & Health Care Program, along 
with many members of its more 
than 20 full time faculty and adjunct 
instructors, celebrated the successes 
of each of the 25 exemplary health 
law certificate students. This was 
the 22nd year that the Law & Health 
Care Program awarded Health Law 
Certificates to students who completed 
the concentration in health law, which 
requires that the students take 17 of 
their 85 law school credits in health 
law, participate in a health law clinic 
or externship, and write a scholarly 
paper on a health law topic. Most of 
the students went well beyond the 
minimum health law credits and 
engaged in numerous and varied 
externships and activities, which 
made the L&HCP class of 2019 a 
wonderfully rich and active group of 
students.
Many certificate recipients showed 
outstanding leadership throughout 
their law school careers, including 
at the helm of the Journal of Health 
Care Law and Policy, which serves 
as a forum for the interdisciplinary 
discussion of leading issues in health 
law, medicine, and health policy, and 
the Student Health Law Organization, 
which does a wonderful job of 
developing events and opportunities 
for students. Other health law students 
represented the law school proudly in 
the national health law competitions, 
including fielding a strong team 
in Maryland Carey Law’s Health 
Law Regulatory and Compliance 
Competition. These are just a few of 
the impressive endeavors undertaken 
by this special group of students. 
Health law students often come to the 
program with impressive academic 
credentials from other prestigious 
institutions. Many of this year’s 
graduates have advanced degrees, 
including master’s or doctoral degrees 
in Pharmacy, Public Health, and 
Business Administration. Certificate 
recipients will go on to work in a 
variety of impressive jobs, including 
in large law firms, federal agencies, 
and judicial clerkships, but every 
recipient graduates well prepared for a 
successful, rewarding career in health 
law and policy. Below, we highlight 
just a few of our exceptional 2019 
graduates and their achievements.
Ashley Creech
Ashley Creech was a keen student of health law and leader on campus and beyond. 
Ashley was an outstanding leader for the Journal of Health Care Law and Policy as 
its editor-in-chief. She inspired the entire board and group of editors to carefully and 
expertly prepare articles for publication, and together, they ensured that the journal 
remains an impressive venue for serious research. Ashley also mentored a very busy and 
high-achieving group of students, and her work leading the journal received the highest 
praise from faculty leaders. According to Professor Frank Pasquale, faculty advisor for 
the Journal of Health Care Law and Policy, who had Ashley in his class, Ashley is also 
an extraordinarily conscientious and thoughtful student. Ashley writes compellingly 
and her work is very carefully considered. In the classroom, Ashley dedicated herself to 
mastering the material, especially in the very comprehensive and challenging Health Care Law and Policy course. Professor Pasquale 
also described her as “terrific” and “involved in the law school community and beyond,” stating that Ashley “will be an excellent 
counselor to both business and government leaders.” Ashley will begin her legal career at Epstein, Becker & Green, P.C.
2019 Health Law Certificate Graduates 
Celebrated at Annual Reception
Professor Karen Rothenberg, Ashley Creech, and 
Professor Diane Hoffmann
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Lysette Deshields
Lysette Deshields came to the law school already having another professional degree, 
a Doctor of Pharmacy. And, already having a full-time job at the Food and Drug 
Administration (FDA) as a regulatory officer, Lysette came to Maryland as an evening 
student. She is also a lieutenant commander in the U.S. Public Health Service. Professor 
Diane Hoffmann met Lysette in the spring of 2017 when she was a student in Hoffmann’s 
Critical Issues in Health Care course, a multidisciplinary course that includes law, 
medicine, nursing, pharmacy, social work, graduate public health and sometimes dental 
students. Hoffmann remembers that “although she was quiet in the class, Lysette ended 
up with the highest grade of any law student.” Lysette’s law school work showed that 
in addition to the analytical skills she honed in pharmacy and law school, Lysette is 
a compassionate person who cares about others and is family oriented. Her outside experience includes having delivered patient 
counseling and drug utilization review for patients during a Haiti Medical Mission. Hoffmann remarked that Lysette’s “combination of 
analytical skills and compassion for others will serve her well as she pursues a career that takes advantage of her background as both a 
pharmacist and now a lawyer.” Lysette will put these skills to good use as she continues her career at the FDA’s Office of Compliance. 
Jaclyn Fonteyne
Jaclyn Fonteyne has been described by her clinical supervisor, Professor Kathleen Hoke, 
as having a “larger than life presence in the Public Health Law Clinic.” Her success in the 
clinic and beyond can be attributed not only to her positive attitude, but also to her ability 
to receive advice and turn in a final work product that reflected her strong researching 
and writing skills as well as her ability to listen to and incorporate feedback. Jaclyn has a 
special interest in food and drug law, which she put to good use as a Public Health Law 
Clinic student. One of the projects Jaclyn worked on during her time in the clinic was 
testimony before the Maryland House and Senate on a bill that will take effect this fall 
making 21 the new minimum age for purchasing tobacco products in the state. According 
to Hoke, “Jaclyn was poised and engaging during her testimony, but her substantive 
contributions to the bill behind the scenes were just as valuable.” In addition to her clinical work, Jaclyn was involved in many other 
student organizations and activities, including as an editor of the Maryland Law Review, peer advisor, teaching fellow, and member of 
the Alternative Dispute Resolution Team and the Student Health Law Organization. Among her other attributes, Jaclyn is also fluent 
in both French and German, having worked for a pharmaceutical company in Germany prior to law school. Jaclyn started in the Food, 
Drug, and Medical Device Regulatory Practice of Sidley Austin LLP’s Washington, D.C. office this fall.
Sarah Wicks
Sarah Wicks began her legal career at Hyman, Phelps & McNamara, P.C. this fall, where 
she is serving clients in the pharmaceutical and biotechnology industry using her strong 
knowledge of regulations and intellectual property transactions. Her law school record 
clearly shows her devotion to mastering those subject areas. During law school, Sarah 
served as a research assistant for faculty members and the Mississippi Center for Justice, 
a student attorney in the Intellectual Property Clinic, and a healthcare consulting firm 
intern at the United States Court of Federal Claims, the FDA, and a major pharmaceutical 
company, to name just a few of her many valuable experiences. During law school, she 
also earned her master’s degree in Public Health from the Johns Hopkins Bloomberg 
School of Public Health. She was a member of the Journal of Health Care Law and 
Policy, the Maryland Intellectual Property Student Association, and the Student Health Law Organization, and she co-authored a paper 
published in April in the International Journal of Pharmaceutics. There is no doubt that Sarah will excel in the legal profession, just as 
she did at Maryland. ■
Lysette Deshields and Professor Diane Hoffmann
Professor Kathleen Hoke, Jaclyn Fonteyne, and 
Professor Diane Hoffmann
Professor Leslie Meltzer Henry, Sarah Wicks, and 
Professor Diane Hoffmann
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9th Annual Health Law Regulatory and Compliance Competition
The Health Law Regulatory and Compliance Competition is a unique and innovative competition that 
challenges students to navigate through the complex regulatory landscape of health care law, including 
compliance with health care regulations and FDA law. The competition will be held on Saturday, February 
22, 2019, from 8:00 a.m. until 3:00 p.m. at the University of Maryland Francis King Carey School of Law in 
Baltimore, Maryland. 
About the Competition
The competition requires teams of 2-3 students to analyze a hypothetical fact pattern involving various 
interactions between health care stakeholders and entities participating in several health care activities 
that necessitate regulatory and compliance oversight. The fact pattern will be given to teams the day of 
the completion, and students will have approximately 1.5 hours to analyze the problem. Teams will then 
present their findings and recommendations to a panel of practicing regulatory and compliance attorneys. 
The 9th annual competition will focus on several interactions between various health care stakeholders, 
including hospitals, physicians, drug and device manufacturers and related third parties.
Call to Compete
If you would like to have a team from your law school participate in the competition, you can find 
additional details and information about how to register at https://www.law.umaryland.edu/Programs-
and-Impact/Health-Law/HLRCC/.
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